Business
China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") against Harbour BioMed's patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0, the "HCAb Patent"), the China
About this update from Hbm Holdings Ltd.
[{"type":"text","content":"CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, June 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced key developments in its intellectual property (IP) protection efforts. Following an invalidation request filed by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") against Harbour BioMed's patent entitled "Binding Molecule" (Patent Application No. CN201210057668.0, the "HCAb Patent"), the China National Intellectual Property Administration ("CNIPA") issued a final decision on June 5, 2025, upholding the patent under Articles 22.3, 26.3, 26.4, and 33 of the Patent Law of the People's Republic of China. The HCAb patent covers a method for producing fully human heavy chain-only antibodies (HCAbs) utilizing transgenic animals.","length":1030,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Harbour BioMed)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Harbour BioMed)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":159,"url":"https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QANxnzzeBFHKxcqoWHourA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/47f569ac406a18e992467aae42c1112a","width":400,"height":159}},"href":"https://mma.prnewswire.com/media/1096360/HB_for_email_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"On September 27, 2024, Harbour BioMed filed a patent infringement lawsuit with the Shanghai Intellectual Property Court against Biocytogen, alleging that its RenNano platform infringes Harbour BioMed's HCAb Patent. Biocytogen subsequently challenged the court's jurisdiction, first through an objection submitted to the Shanghai Intellectual Property Court on November 8, 2024, and later through an appeal to the Supreme People's Court of the People's Republic of China on March 14, 2025. On May 27, 2025, the Supreme People's Court of the People's Republic of China issued a final ruling, dismissing t...